PureTech Health (PRTC) Net Income towards Common Stockholders (2023 - 2025)
PureTech Health (PRTC) reported Net Income towards Common Stockholders of -$44.6 million for Q2 2025, down 6.78% year-over-year from -$47.8 million in Q2 2024, and down 6.78% quarter-over-quarter from -$41.8 million in Q4 2024.
PureTech Health (PRTC) Net Income towards Common Stockholders (2023 - 2025) Analysis & Trends
PureTech Health (PRTC) has 3 years of Net Income towards Common Stockholders data on file, last reported at -$44.6 million in Q2 2025.
- Net Income towards Common Stockholders for Q2 2025 came in at -$44.6 million, down 6.78% year-over-year; the trailing twelve-month figure through Dec 2025 was -$128.2 million (down 18.06% YoY), and the FY2025 annual result was -$109.7 million, down 305.08% from the prior year.
- Net Income towards Common Stockholders fell to -$44.6 million in Q2 2025 per PRTC's latest filing, from -$41.8 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$25.0 million in Q4 2023 and troughed at -$44.6 million in Q2 2025.
- A 3-year average of -$38.3 million and a median of -$41.8 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders tumbled 67.07% in 2024, then retreated 6.78% in 2025.
- A 3-year view of Net Income towards Common Stockholders shows it stood at -$25.0 million in 2023, then plunged by 67.07% to -$41.8 million in 2024, then decreased by 6.78% to -$44.6 million in 2025.
- Business Quant data shows PRTC's Net Income towards Common Stockholders at -$44.6 million in Q2 2025, -$41.8 million in Q4 2024, and -$41.8 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | PureTech Health | 86.36 Mn | -190.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -44.61 Mn |
| Dec 31, 2024 | -41.77 Mn |
| Jun 30, 2024 | -41.77 Mn |
| Dec 31, 2023 | -25.00 Mn |